RBCC Partner n3D Signs Research Sponsorship Agreement with Prominent Medical School





 Rainbow Coral Corp. (OTCBB: RBCC) partner Nano3D Biosciences (n3D) has just inked an important sponsored research agreement with the prestigious University of Texas Health Science Center at Houston (UTHealth) Department of Obstetrics, Gynecology, and Reproductive Sciences. The agreement covers studies on personalized pre-term labor management and treatments.
“Thanks to this milestone agreement, we can make significant strides towards managing premature labor,” said n3D President and Chief Science Officer Glauco Souza. “Study after study has shown that pre-term labor and premature birth often lead to health problems later on for the child. Whatever we can do to help delay early delivery may reduce the short- and long-term negative outcomes for mother and child. We’re eager to apply our magnetic 3D bioprinting technology in this underserved area of medicine.”
RBCC CEO Kimberly Palmer added, “We hope this vital research will lead to new and beneficial medicines for women the world over. We’re glad to be a part of this work and look forward to what these studies will produce.”
Pre-term labor and pre-term birth are defined as labor or birth occurring at least three weeks before a baby’s due date. In 2012, pre-term birth affected more than one in nine babies born in the U.S. and preterm birth-related causes of death accounted for 35 percent of all infant deaths in 2010.

The prenatal testing industry, including research on delaying pre-term labor and birth, is a growing field of study and is expected to reach $3.6 billion dollars by 2019.

RBCC and n3D also recently announced an agreement to begin distribution of 3D bioprinting technology.

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com.For investment information and performance data on the Company,please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.